Search

Author/Creator Serke, M

1. 1508TiPDurvalumab in frail and elder patients with stage four NSCLC: The DURATION trial. (23rd October 2018)

Authors:
Kuon, J; Bozorgmehr, F; Schneider, M A; Krisam, J; Lasitschka, F; Serke, M; Schuette, W; Moosmann, N; Gleiber, W; Faehling, M; Wermke, M; Schuett, P; Boesche, M; van Laak, V; Fischer von Weikersthal, L; Ulmer, M; Meyer zum Büschenfelde, C; Fischer, J R; Thomas, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. (23rd August 2018)

Authors:
Kron, A; Alidousty, C; Scheffler, M; Merkelbach-Bruse, S; Seidel, D; Riedel, R; Ihle, M A; Michels, S; Nogova, L; Fassunke, J; Heydt, C; Kron, F; Ueckeroth, F; Serke, M; Krüger, S; Grohe, C; Koschel, D; Benedikter, J; Kaminsky, B; Schaaf, B
Journal:
Annals of oncology
Issue:
Volume 29:Number 10(2018)
Page Start:
2068
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search